COMMUNIQUÉS West-GlobeNewswire

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12/06/2024
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines [...]
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12/06/2024
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a [...]
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
12/06/2024
The cost of a rescheduled shareholder meeting could reach $100,000 NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that [...]
Clearday Supports National Health Observances
12/06/2024
San Antonio, TX, June 12, 2024 (GLOBE NEWSWIRE) -- Clearday (OTC- CLRD), supports the post on May 29, 2024, from the Office of Disease Prevention and Health Promotion. Said office features monthly National Health [...]
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
12/06/2024
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a [...]
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12/06/2024
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the [...]
Tevogen Bio Set to Join Russell 3000® Index
12/06/2024
WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically [...]
Entourage Announces Results of 2024 Annual General Meeting of Shareholders
12/06/2024
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Entourage Health Corp. ( TSX-V:ENTG ) ( OTCQX:ETRGF ) ( FSE:4WE ) (“ Entourage ” or the “ Company ”), a Canadian producer and distributor of award-winning cannabis products, is [...]
Sanofi: Information concerning the total number of voting rights and shares – May 2024
12/06/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
12/06/2024
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
12/06/2024
SANTA ANA, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Building Awareness of Mental Health Issues in the Workplace: River Oaks Treatment Center Executive Speaks at Tampa LGBT Chamber of Commerce Luncheon
12/06/2024
RIVERVIEW, Fla., June 12, 2024 (GLOBE NEWSWIRE) -- River Oaks Treatment Center, a leading provider of addiction treatment services, is taking a proactive approach to raise awareness about mental health issues within the [...]
SAFE - First implantations of the Sycamore device in Switzerland
12/06/2024
First implantations of the Sycamore device in Switzerland Fleurieux-sur-l’Arbresle - France – June 12, 2024 at 6 p.m . Safe SA, announces the first implantations of Sycamore devices by Professor Maestretti, at the [...]
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
12/06/2024
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse NANTES, France, June 12, 2024 – 6:00pm CET In this [...]
SAFE - Premières implantations du dispositif Sycamore en Suisse
12/06/2024
Premières implantations du dispositif Sycamore en Suisse Fleurieux-sur-l’Arbresle - France - le 12 juin 2024 à 18h . Safe SA, annonce les premières implantations de dispositifs Sycamore par le Professeur Maestretti, à l [...]
Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules
12/06/2024
Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules Par le Dr Stephen Liu et le Pr Benjamin Besse NANTES [...]
AAPS Calls for Overruling Jacobson v. Massachusetts, upon Which Vaccine Mandates Are Based
12/06/2024
TUSCON, Ariz., June 12, 2024 (GLOBE NEWSWIRE) -- In its filing with the U.S. Supreme Court on June 10, the Association of Physicians and Surgeons (AAPS) calls for overruling the century-old precedent of Jacobson v. [...]
Positron Corporation Enters Agreement to Acquire FDA 510(k) for NeuSight PET-CT
12/06/2024
Niagara Falls, NY, June 12, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission [...]
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
12/06/2024
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]

Pages